Randomized, Double-blind, Placebo, Positive-controlled Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis
Latest Information Update: 22 Jul 2024
Price :
$35 *
At a glance
- Drugs Tocilizumab biobetter (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Beijing Weidejie Biotechnology
- 15 Jun 2024 Results assessing the comparative efficacy and safety of VDJ-001 in patients with rheumatoid arthritis following its pre-clinical and early clinical evaluation. , presented at the 25th Annual Congress of the European League Against Rheumatism
- 01 Aug 2023 New trial record